Company Overview and News

0
Millennium Minerals updates Redbeard gold ore reserve, mining to start this month

2018-07-03 proactiveinvestors.com.au
Millennium Minerals Ltd (ASX:MOY) has upgraded the probable ore reserve for Redbeard open pit oxide deposit within its Nullagine project area, prior to the start of mining later this month.
MOY MMMDF

6
International Prospect Ventures Enters Into LOI for Acquisition of an NSR on the Comet Well Property in Western Australia

2018-06-28 globenewswire
THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES
MOY PACXF MMMDF NSRPF DTEMF NVO MALRY MALRF MIN

0
Millennium on track to hit 100,000oz gold target

2018-06-25 australianmining.com.au
Millennium Minerals is set to bring its sixth and new mining centre at the Nullagine gold project in the Pilbara region of Western Australia next month, following a resource grade increase in the latest Redbeard oxide resource drilling.
MOY MMMDF

0
Millennium secures $18m loan facility

2018-06-06 businessnews.com.au
Millennium Minerals has secured a $17.5 million loan facility with Investec to fund an expansion of the company’s Nullagine gold project in the Pilbara.
MOY MMMDF

0
Millennium Minerals secures $17.5m for WA plant expansion

2018-06-06 australianmining.com.au
Perth-based Millennium Minerals has received a $17.5 million funding commitment from Investec Australia to expand the processing plant at its Nullagine gold project in the Western Australia.
MOY MMMDF

0
Millennium Minerals targets gold production of up to 80,000 ounces at Nullagine in 2018

2018-03-19 proactiveinvestors.com.au
Millennium Minerals Ltd’s (ASX:MOY) expects to achieve gold production in a range between 75,000 ounces and 80,000 ounces in 2018.
MOY MMMDF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MOY / MILLENNIUM MINERALS LIMITED on message board site Silicon Investor.

Moyco CMP Slurries - CEO Says MOYDOW MINES (MOY.TO)